Navigation Links
H5N1 vaccine could be basis for life-saving stockpile

Scientists at St. Jude Children's Research Hospital have announced that a vaccine they developed a few years ago against one antigenic variant of the avian influenza virus H5N1 may protect humans against future variants of the virus. Vaccines based on this model might therefore be suitable for stockpiling for use during a pandemic (worldwide epidemic) until a new vaccine could be developed specifically against the variant causing the outbreak, the researchers said. An antigen is a molecule that stimulates production of antibodies by the immune system.

A prepublication report on the study appears in the online issue of Journal of Infectious Diseases (JID).

The researchers showed that the vaccine completely protected ferrets from a lethal nasal infection against not only the original virus the vaccine was made to thwart, but also against a newer variant that has already proved fatal to humans. The ferrets experienced a more significant reduction of virus multiplication than otherwise would have occurred, the researchers reported. Moreover, the infections failed to spread out of the upper respiratory tract to the lungs or brain.

"These findings are especially significant because ferrets are known to be an excellent and accurate model of influenza infection and immune response in humans," said Elena Govorkova, Ph.D., a staff scientist in the Department of Infectious Diseases at St. Jude. "Restricting the infection to the upper respiratory tract is important since in humans the virus has been isolated from specimens taken from the cerebrospinal fluid, feces, throat and blood serum. Therefore, limiting the spread of virus in an infected human is crucial to saving that person's life." Govorkova is the lead author of the JID paper and led the research team conducting the study.

The team also showed that the optimal strategy for vaccination of immunologically naïve individuals will be the use of two doses, which in the ferrets triggered mo re antibody protection than a single dose. Immunologically naïve individuals are those whose immune systems have not been stimulated to respond to a particular antigen.

The St. Jude study was the first one to show cross-reactive immunity against current H5N1 variants in ferrets, according to Robert Webster, Ph.D., a member of the Infectious Diseases department and holder of the Rose Marie Thomas Chair at St. Jude. Webster is an internationally renowned expert on avian influenza viruses and is senior author of the report in JID.

Cross-reactive immunity is the protection that a virus vaccine confers against not only the same virus, but also against variants of the original virus. "Such cross-protection would allow the use of a stockpiled vaccine until a vaccine against the specific variant causing the outbreak is developed," Webster said. "So our success with ferrets is extremely promising news."

Using reverse genetics, the team mixed genes from a safe, laboratory bird flu virus with a gene for the hemagglutinin (HA) protein from the H5N1 virus isolated in Hong Kong. The virus uses the HA proteins on its surface to infect cells in the respiratory tract. The resulting vaccine had the outside appearance of a dangerous virus that would stimulate the immune system, but the inside genes of a harmless variety of virus that could not cause disease. The St. Jude team was the first to use reverse genetics to make a vaccine against H5N1 that moved out of the laboratory and into clinical trials: http://www.stjude.org/media/0,2561,453_5484_4638,00.html.


'"/>

Source:St. Jude Children's Research Hospital


Related biology news :

1. Research advances quest for HIV-1 vaccine
2. A much-needed shot in the arm for HIV vaccine development
3. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
4. Gene vaccine for Alzheimers disease shows promising results
5. Influenza vaccine uses insect cells to speed development
6. Norovirus, AIDS vaccine and Hepatitis Virus
7. HIV vaccine trial breaks ground for future research
8. Live vaccines more effective against horse herpes virus
9. NIAID begins clinical trial of West Nile virus vaccine
10. Designing vaccines by computer
11. Wake Forest scientists find new combination vaccine effective against plague
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/11/2017)... 11, 2017 Research and Markets has announced ... report to their offering. ... global eye tracking market to grow at a CAGR of 30.37% ... Tracking Market 2017-2021, has been prepared based on an in-depth market ... landscape and its growth prospects over the coming years. The report ...
(Date:4/5/2017)... , April 5, 2017  The Allen Institute for ... Cell Explorer: a one-of-a-kind portal and dynamic digital window ... imaging data, the first application of deep learning to ... stem cell lines and a growing suite of powerful ... for these and future publicly available resources created and ...
(Date:4/3/2017)... 2017  Data captured by IsoCode, IsoPlexis ... a statistically significant association between the potency ... and objective response of cancer patients post-treatment. ... whether cancer patients will respond to CAR-T ... as to improve both pre-infusion potency testing and ...
Breaking Biology News(10 mins):
(Date:4/21/2017)... ... April 21, 2017 , ... The 2017 Colorado Manufacturing Awards ... 30 nominees and well as the first-year award for 2017 Manufacturing Women of ... was hosted by CompanyWeek and Manufacturers Edge, among other sponsors. , The ...
(Date:4/21/2017)... ... April 21, 2017 , ... Frederick ... a range of emerging bio and technology start-ups, is hosting “Celebration Friday” (a ... double event will start with libations and networking at 3:30 p.m. at FITCI’s ...
(Date:4/20/2017)... ... April 20, 2017 , ... USDM Life Sciences , the ... and healthcare industries, is pleased to announce Holger Braemer as Vice President ... Europe GmbH” based in Germany. , Braemer is an integral part of USDM’s ...
(Date:4/20/2017)... ... April 20, 2017 , ... Parallel6™ , the leader ... announced today that they were named one of the 2017 Top 10 eClinical ... developments in the pharmaceutical industry. , “We take pride in honoring Parallel6 as one ...
Breaking Biology Technology: